Aardvark Therapeutics (NASDAQ:AARD) Insider Sells 14,754 Shares of Stock

Aardvark Therapeutics, Inc. (NASDAQ:AARD) insider Nelson Sun sold 14,754 shares of Aardvark Therapeutics stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $5.00, for a total transaction of $73,770.00. Following the sale, the insider directly owned 97,475 shares of the company’s stock, valued at $487,375. This trade represents a 13.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Nelson Sun also recently made the following trade(s):

• On Friday, September 11th, Nelson Sun sold 62,000 shares of Aardvark Therapeutics stock. The stock was sold at an average price of $5.18, for a total transaction of $321,160.00.

Aardvark Therapeutics Price Performance

AARD traded up $0.12 during trading on Friday, reaching $5.13. 276,559 shares of the stock traded hands, compared to its average volume of 128,424. The stock’s 50-day simple moving average is $6.29 and its two-hundred day simple moving average is $5.53. Aardvark Therapeutics, Inc. has a fifty-two week low of $3.35 and a fifty-two week high of $17.94. The stock has a market cap of $112.24 million, a price-to-earnings ratio of -1.60 and a beta of 3.74.

Aardvark Therapeutics (NASDAQ:AARD) last issued its earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.21. Research analysts anticipate that Aardvark Therapeutics, Inc. will post -3.17 earnings per share for the current fiscal year.

More Aardvark Therapeutics News

Here are the key news stories impacting Aardvark Therapeutics this week:

• Positive Sentiment: No company-specific clinical, regulatory, or financial improvement was reported in the latest updates. The absence of new adverse operating news may limit additional selling pressure.
• Neutral Sentiment: Several law firms—including Hagens Berman, Rosen Law Firm, SBS Law, Pomerantz, Faruqi & Faruqi, and Bernstein Liebhard—are soliciting investors to seek lead-plaintiff status by October 13, 2026. These announcements largely repeat the same underlying lawsuit rather than representing separate cases. Hagens Berman investor notice
• Neutral Sentiment: A reported September short-interest update showed zero shares sold short, but the figures appear incomplete or unreliable because the reported change was listed as “NaN.” It therefore provides little useful insight into trading direction.
• Negative Sentiment: The securities class action covers investors who bought Aardvark shares in or traceable to the February 2025 IPO, or who purchased securities between February 13, 2025, and May 14, 2026. The litigation alleges violations of federal securities laws by the company and certain officers and directors. Pomerantz class-action announcement
• Negative Sentiment: One investor notice alleges that IPO materials described Aardvark’s ARD-101 drug candidate as 99% restricted to the gut and reported no serious adverse events, while allegedly omitting safety risks that later led to an FDA clinical hold. These remain allegations, but the claims create potential legal costs, uncertainty, and reputational damage. AARD shareholder alert

Institutional Trading of Aardvark Therapeutics

Several large investors have recently modified their holdings of AARD. SymBiosis Capital Partners LLC acquired a new position in Aardvark Therapeutics in the 4th quarter valued at $6,255,000. Millennium Management LLC acquired a new position in shares of Aardvark Therapeutics during the 3rd quarter worth about $4,248,000. BlackRock Inc. acquired a new position in shares of Aardvark Therapeutics during the second quarter worth approximately $1,077,000. Geode Capital Management LLC raised its stake in Aardvark Therapeutics by 53.5% during the 4th quarter. Geode Capital Management LLC now owns 297,865 shares of the company’s stock valued at $3,910,000 after purchasing an additional 103,830 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of Aardvark Therapeutics by 20.6% in the third quarter. Vanguard Group Inc. now owns 555,721 shares of the company’s stock valued at $7,386,000 after buying an additional 94,744 shares during the period.

Analysts Set New Price Targets

AARD has been the topic of several analyst reports. Morgan Stanley restated an “underweight” rating and set a $3.00 price target (down from $7.00) on shares of Aardvark Therapeutics in a research note on Friday, May 15th. Weiss Ratings raised shares of Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 2nd. BTIG Research cut Aardvark Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th. HC Wainwright reissued a “neutral” rating and set a $6.00 price objective on shares of Aardvark Therapeutics in a report on Monday, July 20th. Finally, Wall Street Zen raised Aardvark Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Aardvark Therapeutics has a consensus rating of “Hold” and an average target price of $15.33.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.